ANONDITA
Anondita Medicare financials
- Market cap
- ₹2.2k Cr
- Sector
- Fast Moving Consumer Goods
- Calls analysed
- 1
Anondita Medicare Ltd Q4 FY26
What went well
- H2 FY26 Revenue from operations was INR 83.32 crores, an 82.77% growth compared to INR 45.59 crores in H2 FY25.
- FY26 Revenue from operations was INR 137.42 crores, a 78.48% growth compared to INR 76.99 crores in FY25.
- FY26 EBITDA was INR 51.51 crores, a 99.97% growth compared to INR 25.79 crores in FY25.
What to watch
- Operating cash flow was INR 10.6 crores despite a PAT of INR 34 crores, indicating a cash conversion ratio of only 31%.
- Trade receivables grew by INR 25 crores and inventory by over INR 7 crores, impacting cash flow.
What Anondita Medicare Ltd does
Anondita Medicare manufactures male and female condoms and related sexual-wellness/healthcare products at its own facility in Noida, Uttar Pradesh, selling under its flagship COBRA brand while historically also contract-manufacturing for third-party pharma brands (including, in the past, Mankind Pharma's Manforce). It earns through a pan-India wholesale network of super stockists, distributors and retailers, supplemented by exports to select international markets. The company has recently added female latex condom production and has expanded the COBRA range into pregnancy test kits, lubricants and related tablets alongside its core condom and surgical-glove lines.
- Annual installed condom production capacity
- 869 million pieces
- Manufacturing lines
- 15 operational, plus 12 more under installation (WIP)
- Manufacturing facility
- Single integrated facility in Noida, Uttar Pradesh (~9,290 sq. mt. built-up area)
- Distribution network
- 26 super stockists, 195 distributors, 4,569 retailers across India
- Export markets
- 7 countries — Brazil, South Africa, Uzbekistan, Nepal, Kenya, Cuba, UAE
- Production speed at full capacity
- ~12,100 condoms produced every 3 minutes
Guidance record · Q4 FY26
what the last two calls moved 10 tracked 0 delivered 0 missed 10 open- Total Revenue open said Q4 FY26 Promised: Touch INR 1,000 crores revenue within the next 2 years Q4 FY26: In response to an analyst question, management committed to reaching INR 1,000 crores in revenue within the next 2 years.
All 10 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 31 | 46 | 54 | 83 |
| EBITDA | 10 | 16 | 19 | 31 |
| Net profit | 6 | 10 | 13 | 21 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +231.4% 1Y
1Y: ₹340.85 on 10 Sept 2025 → ₹1,129.55. High ₹1,233.15 (24 Jun 2026), low ₹340.85 (10 Sept 2025).
How the price took the results
close before → close after
- Q4 FY26
- −3.1%
- 27 May
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Balance sheet
| Year ending | FY25 | FY26 |
|---|---|---|
| Equity capital | ₹18 Cr | ₹18 Cr |
| Reserves | ₹91 Cr | ₹111 Cr |
| Borrowings | ₹47 Cr | ₹34 Cr |
| Other liabilities | ₹21 Cr | ₹22 Cr |
| Total liabilities | ₹176 Cr | ₹185 Cr |
| Fixed assets | ₹13 Cr | ₹84 Cr |
| Capital work in progress | ₹15 Cr | ₹0 Cr |
| Investments | ₹3 Cr | ₹0 Cr |
| Other assets | ₹145 Cr | ₹101 Cr |
| Total assets | ₹176 Cr | ₹185 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Sep 2025, the public added +1.08 pp while DIIs trimmed −0.85 pp. The shareholder count shrank 15% to 530.
- Promoters
- 62.4%
- FIIs
- 3.4%
- DIIs
- 5.7%
- Public
- 28.5%
Since Sep 2025
- Public +1.08 pp
- DIIs −0.85 pp
- FIIs −0.84 pp
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Sageone - Flagship Growth 2 AIF newly disclosed 1.75% held
- Mansi Share & Stock Broking Private Limited newly disclosed 1.63% held
- Vanaja Sundar Iyer newly disclosed 1.59% held
- Siddharth Iyer newly disclosed 1.28% held
- Anupam Ghosh +0.28 pp 61.99% held
- Sonia Ghosh +0.17 pp 0.17% held
- Reshant Ghosh +0.16 pp 0.25% held
The same filing shows 2 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Anondita Medicare Ltd above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Anupam Ghosh | 61.99% | +0.28 pp |
| Moheet Vinodkumar Agarwal | 3.05% | unchanged |
| Sageone-Flagship Growth Oe Fund AIF | 2.92% | −0.09 pp |
| Vikasa India Eif I Fund - Incube Global Opportunities FPI fund | 2.12% | unchanged |
| Ritu Bapna | 1.91% | unchanged |
| Sageone - Flagship Growth 2 AIF | 1.75% | newly disclosed |
| Mansi Share & Stock Broking Private Limited | 1.63% | newly disclosed |
| Vanaja Sundar Iyer | 1.59% | newly disclosed |
| Siddharth Iyer | 1.28% | newly disclosed |
| Sagar P Brahmbhatt | 1.24% | −0.07 pp |
| Reshant Ghosh | 0.25% | +0.16 pp |
| Sonia Ghosh | 0.17% | +0.17 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 25.7% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Anondita Medicare Ltd
Guides on how to read this kind of business and the numbers that matter.